North America Osteoporosis Drugs Market By Route of Administration, By Drug Class, By Country, Industry Analysis and Forecast, 2020 - 2026

The North America Osteoporosis Drugs Market is expected to witness market growth of 3.7% CAGR during the forecast period (2020-2026).

Osteoporosis is the degradation of bones owing to reduced bone density resulting in micro-architectural loss of bone tissue and a greater chance of fracture. This usually occurs at an older age, and women are more vulnerable to it than males by around three or four times. The World Health Organization reports that about 1.66 million hip fractures occur worldwide per year owing to osteoporosis. According to the National Osteoporosis Foundation, about 54 million Americans suffer from osteoporosis. The disease also has a genetic bias in that it affects more Caucasians than Asians. The incidence of the disease is lowest in the African community.

Osteoporosis is induced by low bone mass and tissue degradation, which raises the likelihood of fracture, especially in the spine and wrists. Providers depend on the development of more focused approaches, such as anabolic medications, for successful treatment of the disease. Anabolic agents promote new bone growth, enhance bone density, and increase bone mass, as well as reduce fracture incidence.

The anabolic agent developed by Radium Health Inc for the treatment of osteoporosis in postmenopausal women and the anabolic agent developed for the treatment of osteoporosis associated with prolonged systemic glucocorticoid therapy have also been licensed by the US FDA companies such as Amgen Inc and Astellas Pharma Inc. are now working on producing a bone-forming monoclonal antibody for the treatment medicament. In addition to product approvals, the existence of a promising medication pipeline for osteoporosis should improve the demand for osteoporosis medicines over the coming years.

Based on Route of Administration, the market is segmented into Oral, Injectable and Other Route of Administration. Based on Drug Class, the market is segmented into Bisphosphonates, Rank Ligand Inhibitors, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Other Drug Classes. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC (GSK), Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., Allergan PLC, and Eli Lilly and Company

Scope of the Study

Market Segmentation:

By Route of Administration

• Oral
• Injectable and
• Other Route of Administration

By Drug Class

• Bisphosphonates
• Rank Ligand Inhibitors
• Parathyroid Hormone Therapy
• Calcitonin
• Selective Estrogen Inhibitors Modulator (SERM) and
• Other Drug Classes

By Country

• US
• Canada
• Mexico
• Rest of North America

Companies Profiled

• Amgen, Inc.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline PLC (GSK)
• Merck & Co., Inc.
• Novartis AG
• Pfizer, Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceuticals Industries Ltd.
• Allergan PLC
• Eli Lilly and Company

Unique Offerings from the Publisher

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free